The Journal of Practical Medicine >
The association between C⁃reactive protein/albumin ratio and the risk of cardiovascular events in maintenance hemodialysis patients
Received date: 2023-07-14
Online published: 2024-01-24
Objective To explore the association between C-reactive protein/albumin ratio （CAR） and the risk of cardiovascular events in maintenance hemodialysis（MHD）patients. Methods This study enrolled MHD patients who were treated in the blood purification center of the Second Affiliated Hospital of Guangzhou Medical University between August 2016 to December 2019， and the follow-up deadline was March 31， 2021. Collected the clinical data of patients who conform to the inclusion criteria， including demographic， complications， primary basic disease， biochemical indicators of the patients who underwent 3 months regular dialysis treatment and the occurrence of cardiovascular events during the follow-up period. The Kaplan-Meier method was used to estimate the probability of cardiovascular incidents in MHD patients. The Cox proportional hazards model based on generalized propensity score weighting （GPSW） was used to estimate the relationship between CAR and cardiovascular events in MHD patients. Results A total of 170 eligible objects were included in this study， 64 patients with cardiovascular events （37.6%）. The Cox proportional hazards model which based on GPSW（HRCAR = 2.087， 95%CI： 1.085 ~ 4.015， P = 0.028）， indicated that the hazard ratio of cardiovascular events was 2.087 when the CAR each additional a unit in MHD patients. Conclusion CAR and the risk of cardiovascular events in MHD patients have a significant positive correlation，which can help clinical workers recognize the MHD patients who have high risk of cardiovascular events and intervene in time.
Yuanmei MU , Jiayuan ZHAO , Ying. ZHANG . The association between C⁃reactive protein/albumin ratio and the risk of cardiovascular events in maintenance hemodialysis patients[J]. The Journal of Practical Medicine, 2024 , 40(1) : 72 -78 . DOI: 10.3969/j.issn.1006-5725.2024.01.013
| 1 | ZHANG L X， ZHAO M H， LI Z， et al. China kidney disease network （CK-NET） 2016 annual data report［J］. Kidney Int Suppl （2011）， 2020， 10（2）： e97-e185. |
| 2 | CHAN K， MOE S M， SARAN R， et al. The cardiovascular–dialysis nexus： the transition to dialysis is a treacherous time for the heart［J］. Eur Heart J， 2021， 42（13）： 1244-1253. |
| 3 | AHMED M S， JADHAV A B， HASSAN A，et al. Acute Phase Reactants as Novel Predictors of Cardiovascular Disease［J］. ISRN Inflamm， 2012，2012：953461. |
| 4 | 孙岩， 祁露萱， 李丰， 等. 血清 C 反应蛋白与白蛋白比值对支气管扩张症急性加重的预测价值［J］. 实用医学杂志， 2021， 37（23）： 2998-3002. |
| 5 | CUI X H， JIA Z Q， CHEN D C， et al. The prognostic value of the C-reactive protein to albumin ratio in cancer： an updated meta-analysis［J］. Medicine （Baltimore）， 2020，99（14）：e19165. |
| 6 | 黄琪惠， 张琳. 中性粒细胞/淋巴细胞比值， C-反应蛋白/白蛋白及低钙在重症颅脑损伤并早期呼吸机相关性肺炎的价值分析［J］. 实用医学杂志， 2021， 37（7）： 903-908. |
| 7 | 冉燕， 达静静， 胡英， 等. C 反应蛋白与白蛋白比值可预测急性肾损伤患者的不良预后［J］. 实用医学杂志， 2015， 31（23）： 3895-3897. |
| 8 | HICKS K A， TCHENG J E， BOZKURT B， et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials： a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards （Writing Committee to Develop Cardiovascular Endpoints Data Standards）［J］. J Am Coll Cardiol， 2015， 66（4）： 403-469. |
| 9 | LAI A C， BIENSTOCK S W， SHARMA R， et al. A personalized approach to chronic kidney disease and cardiovascular disease： JACC review topic of the week［J］. J Am Coll Cardiol， 2021， 77（11）： 1470-1479. |
| 10 | 贾凤玉， 孟建中. 慢性肾脏病 （透析） 患者的心血管疾病诊疗指南解读［J］. 中国血液净化， 2011， 10（10）： 570-575. |
| 11 | WANG Y H， GAO L. Inflammation and cardiovascular disease associated with hemodialysis for end-stage renal disease［J］. Front Pharmacol， 2022， 13： 800950. |
| 12 | NOWAK K L， CHONCHOL M. Does inflammation affect outcomes in dialysis patients？［C］ Semin Dial， 2018， 31（4）： 388-397. |
| 13 | ARROYO-ESPLIGUERO R， VIANA-LLAMAS M C， SILVA-OBREGóN A， et al. The role of C-reactive protein in patient risk stratification and treatment［J］. Eur Cardiol， 2021， 16：e28. |
| 14 | BLAKE G J， RIDKER P M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes［J］. J Am Coll Cardiol， 2003， 41（4S）： S37-S42. |
| 15 | KALANTAR-ZADEH K， KILPATRICK R D， KUWAE N， et al. Revisiting mortality predictability of serum albumin in the dialysis population： time dependency， longitudinal changes and population-attributable fraction［J］. Nephrol Dial Transplant， 2005， 20（9）： 1880-1888. |
| 16 | SATILMIS S， KARABULUT A. Value of C-reactive protein/albumin ratio in predicting the development of contrast-induced nephropathy in patients with non-ST elevation myocardial infarction［J］. Angiology， 2020， 71（4）： 366-371. |
| 17 | ?INAR T， ?A?DA? M， RENCüZO?ULLARI ?， et al. Prognostic efficacy of C-reactive protein/albumin ratio in ST elevation myocardial infarction［J］. Scand Cardiovasc J， 2019， 53（2）： 83-90. |
| 18 | SüLEYMANO?LU M， BURAK C， GüMü?DA? A， et al. Assessment of the relation between C-reactive protein to albumin ratio and the severity and complexity of peripheral arterial disease［J］. Vascular， 2020， 28（6）： 731-738. |
| 19 | 杨桂鲜， 吴艳波， 王晞， 等. 维持性血液透析患者微炎症与心血管事件关系研究［J］. 实用医学杂志， 2012， 28（2）： 251-253. |
| 20 | 中国医师协会肾脏内科医师分会，中国中西医结合学会肾脏疾病专业委员会营养治疗指南专家协作组.中国慢性肾脏病营养治疗临床实践指南（2021版）［J］.中华医学杂志，2021，101（8）：539-559. |
| 21 | SANT′ANA M， GAMEIRO J， COSTA C， et al. C-reactive protein-to-albumin ratio and six-month mortality in incident hemodialysis patients［J］. Ren Fail， 2023， 45（1）： 2182615. |
| 22 | STENVINKEL P， HEIMBüRGER O， PAULTRE F， et al. Strong association between malnutrition， inflammation， and atherosclerosis in chronic renal failure［J］. Kidney Int， 1999， 55（5）： 1899-1911. |
| 23 | 张燕京， 吴华， 陈献广， 等. 维持性血液透析患者白蛋白和 C 反应蛋白水平与预后的关系［J］. 中国血液净化， 2011， 10（8）： 420-425. |
| 24 | TARDIF J C， KOUZ S， WATERS D D， et al. Efficacy and safety of low-dose colchicine after myocardial infarction［J］. N Engl J Med， 2019， 381（26）： 2497-2505. |
| 25 | RIDKER P M， MACFADYEN J G， EVERETT B M， et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab： a secondary analysis from the CANTOS randomised controlled trial［J］. The Lancet， 2018， 391（10118）： 319-328. |
| 26 | NATALE P， PALMER S C， SAGLIMBENE V M， et al. Antiplatelet agents for chronic kidney disease［J］. Cochrane Database Syst Rev， 2022， 2（2）：CD008834. |
/
| 〈 |
|
〉 |